Vascular Access Devices Market - Growth, Trends, and Forecast (2019 - 2024)

Market Overview

Over the last decade, there has been a rise in the prevalence of several chronic diseases that need vascular access treatment. Some of the major chronic diseases include cancer, kidney failure, and heart diseases, among others. Along with these, there are several lifestyle disorders relating to chronic and non-communicable disease conditions, such as hypertension, diabetes, obesity, and depression, among others, which need critical care during their hospitalization.

The prevalence of end-stage renal disease (ESRD), worldwide, is further increasing at a significant rate, resulting in chronic kidney disease (CKD). In 2017, in the United States, around 30 million people (15% of US adults) were suffering from chronic kidney disease (CKD). CKD was found to be more common in women (16%) than in men (13%). For patients undergoing dialysis treatment, the ideal method of vascular access is through an arteriovenous fistula (ANF), by referring to a nephrologist about replacement therapy. The vascular access catheter devices are also significantly used in the case of chemotherapies. According to the Center for Disease Control and Prevention (CDC), in the United States, nearly 0.65 million cancer patients receive chemotherapy in an outpatient oncology clinic annually. With the rising prevalence of chronic diseases and lifestyle disorders, the vascular access procedures are increasingly being used for intravenous antibiotic treatment, long intravenous nutritional support, and drawing of blood samples.

Thus, during the forecast period, a high rise is expected in the prevalence of these diseases, both in developed and highly emerging markets, such as India, China, and Middle Eastern countries, which are expected to draw an attention of several multinational medical devices companies to invest and launch new products, thus, acting as one of the major drivers for this market.

Scope of the Report

Vascular access devices (VADs) are inserted into the veins for diagnostic and therapeutic reasons, such as blood sampling, central venous pressure readings, administration of medication, fluids, total parenteral nutrition (TPN), and blood transfusions. These are inserted peripherally or centrally. The choice of device for each patient differs and multiple types of devices may be required at a time, as a single device may not be able to meet all the requirements.

Key Market Trends

Application Segment is Dominated by the Administration of Fluid and Nutrition

Despite the move toward increased patient involvement in the decisions affecting their care, there is little evidence published to support user involvement in the selection of vascular access devices. There is, however, increasing evidence of patient experiences linked with vascular access and infusion therapies.

Peripherally, inserted central catheters (PICC) are most commonly inserted via the basilic, brachial or cephalic veins for the parenteral delivery of nutrition. All patients undergoing emergency of elective surgery require monitoring of intravenous fluids and blood components through vascular access devices. In the case of ESRD and CKD, vascular access plays a highly essential role for fluid resuscitation, fluid administration, electrolytes, nutrition or medication, laboratory testing, and monitoring of hemodynamics. During advanced life support in hospitals, vascular access is a primary requirement for fluid administration. The range of applications, in which vascular access can be used for fluids transmission is high, including critically ill patients and children with shock, where intraosseous cannulation (IO) is highly important. IO access has a high success rate in critically ill children.

Short-term vascular access is frequently required by hospitalized children through fluids and nutrition. Some of the major companies helping fluid administration are Teleflex, 3M, Medline Industries, and Mobilex USA.

North America to Dominate the Market Over the Forecast Period

The demand for vascular access devices has increased in the United States in the past five years, with a high percentage of patients receiving some sort of vascular access treatment during their hospitalization.

The US Food and Drug Administration (FDA) proposed stringent guidelines, in terms of usage, owing to the increased vascular infections. The US FDA has released regulated guidelines for the hemodialysis vascular access, as well as certain laws and regulations affecting the use of these products, along with the guidelines to certain issues raised and end points proposed by the kidney health initiative. A high percentage of catheters, especially PICC, is being used by more than 80% of hemodialysis patients. An increase in the percentage of usage, with more than 90 days, is also recorded during the long stay of the patient.

Additionally, in a large number of cases of all the end-stage renal disease (ESRD), dialysis patients are treated via a catheter, which is performed in an outpatient setting, thus, reducing the hospitalization of ESRD patients by allowing the non-emergency interventional procedures to be carried out. The factors, such as government guidelines for the regulation of medical devices by the company, and better healthcare infrastructure, etc., play a key role in increasing the business and in the launching of new products by multinational companies, and thereby, contributing the market growth.

Competitive Landscape

The vascular access devices market is highly competitive and there are several small to mid-sized companies that are posing strong competition to gain the market share. However, few companies that are doing a good business in the market include B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, NIPRO Medical Corporation and Fresenius Medical Care.


This product will be delivered within 2 business days.